Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
Abstract
Tumor-associated macrophages (TAMs) are known to contribute to adaptive resistance to anti-vascular endothelial growth factor (VEGF) antibody (AVA) therapy in ovarian cancer. BET (bromodomain and extra-terminal domain) inhibitors (BETi) may have unique roles in targeting TAMs. Our objective was to examine the effects of BETi on TAMs, especially in the context of enhancing the efficacy of AVA therapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 30, 2022
- Source ID
- 10.1007/s00432-021-03885-z
Entities
People
- Adrian Lankenau Ahumada
- Anil K. Sood
- Deanna Glassman
- Elaine Stur
- Emine Bayraktar
- Lingegowda S. Mangala
- Nicholas B. Jennings
- Santosh K. Dasari
- Sara Corvigno
- Shannon N. Westin
- Wei Hu
- Yunjie Sun
- Yutuan Wu
Organizations
- National Institutes of Health
- Ovarian Cancer Research Alliance
- United States Department of Defense